The discovery of a new preclinical compound with strong antifungal activity against multidrug-resistant pathogens is described in Nature. The drug, named mandimycin, is a member of a known family of bacterial products with antifungal properties, the polyene macrolides. Unlike known compounds in this family, mandimycin binds to a novel target in the fungal cell membrane and is therefore active against a range of pathogens that are resistant to related compounds. The discovery of a new preclinical compound with strong antifungal activity against multidrug-resistant pathogens is described in Nature. The drug, named mandimycin, is a member of a known family of bacterial products with antifungal properties, the polyene macrolides. Unlike known compounds in this family, mandimycin binds to a novel target in the fungal cell membrane and is therefore active against a range of pathogens that are resistant to related compounds. Cell & Microbiology Molecular & Computational biology Phys.org – latest science and technology news stories
Experimental antifungal compound kills multidrug-resistant fungi
